List view / Grid view
21 September 2017 | By Charles River Laboratories
In this webinar, we highlight in vitro models and phenotypic assays to discover and validate novel targets and promising lead molecules...
Next-generation sequencing (NGS) has greatly increased our understanding of biological phenomena and human disease. In particular, single-cell sequencing is one of the fastest-growing applications...
22 June 2017 | By Charles River Laboratories
40-65% of MS patients have cognitive impairment and touchscreen testing in animal models is a new method to test cognitive issues in MS animal models...
Peer-reviewed paper on how touchscreen testing is a translational tool to assess cognitive function in a mouse model of Alzheimer’s disease...
Peer-reviewed publication on new strategies to target misfolded protein aggregates at various steps of protein production and processing...
Charles River Laboratories International, Inc. (NYSE: CRL) recently announced updates to its expanding oncology discovery business, including significant additions to its online Tumor Model Compendium...
Charles River Laboratories International, Inc. (NYSE: CRL), a leading early-stage contract research organization (CRO), announced the North American launch of its triple-immunodeficient mouse model, known as the NCG model...
3 April 2017 | By Charles River
This webinar reviews standard neuropathic pain models and readouts and will include fine motor kinematic analysis to highlight gait changes...
Quotient Clinical announces that it has acquired QS Pharma from Charles River Laboratories International, Inc...
Quotient Clinical announces that it has acquired SeaView Research, expanding its operations into the USA...
Lorenz Mayr, esteemed Vice President and Global Head of Biological Reagents and Assay Development at AstraZeneca will be joining the expert speaker lineup for the launch conference on Drug Discovery. The event takes place on 27 and 28 April 2017 in London.
12 January 2017 | By ProteinSimple
Single-Cell Western system capable of analysing protein expression in ~1,000 single-cells in parallel to unlock heterogeneity...
1 December 2016 | By Charles River
This webinar details a successful new strategy to identify small molecule therapies to treat protein-destabilizing monogenic disorders...
28 June 2016 | By Merck KGaA
EMD Millipore is continually developing and refining tools and technologies for the study of neuroscience. Researchers can count on our comprehensive portfolio of dependable, high-quality solutions for elucidating questions related to neuroscience...
Pluripotent stem cell research has made extraordinary progress over the past decade. The robustness of nuclear reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) has created entirely novel opportunities for drug discovery and personalised regenerative medicine...
